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Abstract
Background: Pre-eclampsia and eclampsia are serious complications of pregnancy and major causes of maternal
mortality and morbidity worldwide. According to systematic reviews and WHO guidelines magnesium sulphate
injection (MgSO4) should be the first -line treatment for severe pre-eclampsia and eclampsia. Studies have shown
that this safe and effective medicine is unavailable and underutilized in many resource poor countries. The
objective of this study was to identify barriers to the availability and use of MgSO4 in the Zambian Public Health
System.
Methods: A ‘fishbone’ (Ishikawa) diagram listing probable facilitators to the availability and use of MgSO4 identified
from the literature was used to develop an assessment tool. Barriers to availability and use of MgSO4 were
assessed at the regulatory/government, supply, procurement, distribution, health facility and health professional
levels. The assessment was completed during August 2008 using archival data, and observations at a pragmatic
sample of health facilities providing obstetric services in Lusaka District, Zambia.
Results: The major barrier to the availability of MgSO4 within the public health system in Zambia was lack of
procurement by the Ministry of Health. Other barriers identified included a lack of demand by health professionals
at the health centre level and a lack of in-service training in the use of MgSO4. Where there was demand by
obstetricians, magnesium sulphate injection was being procured from the private sector by the hospital pharmacy
despite not being registered and licensed for use for the treatment of severe pre-eclampsia and eclampsia by the
national Pharmaceutical Regulatory Authority.
Conclusions: The case study in Zambia highlights the complexities that underlie making essential medicines
available and used appropriately. The fishbone diagram is a useful theoretical framework for illustrating the
complexity of translating research findings into clinical practice. A better understanding of the supply system and
of the pattern of demand for MgSO4 in Zambia should enable policy makers and stakeholders to develop and
implement appropriate interventions to improve the availability and use of MgSO4.
Background
Pre-eclampsia and eclampsia are serious complications
of pregnancy and major causes of maternal mortality
and morbidity worldwide. In 2002, there were over 4
million cases of pre-eclampsia and eclampsia globally, of
which 63,000 resulted in a maternal death [1]. Estimates
of case fatality rates, based mainly on hospital-based stu-
dies, show that the risk of dying from eclampsia is
approximately 14 times higher in a developing country
compared to a developed country [2].
Clinical evidence from systematic reviews shows that
magnesium sulphate (MgSO4) should be the first -line
treatment for severe pre-eclampsia and eclampsia [3-6].
Since 2003, it has been included on the World Health
Organization’s Model List of Essential Medicines specifi-
cally for the treatment of severe pre-eclampsia and
eclampsia [7]. However, studies show that this safe and
effective medicine is still unavailable and underutilized
in many low and middle income countries [8,9]. The
first step in designing effective interventions to increase
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target the intervention accordingly [10].
The objective of this pilot study was to identify bar-
riers and facilitators to the availability and use of
MgSO4 in the Zambian Public Health System using a
health system approach, to provide information to deci-
sion makers on the most appropriate interventions to
improve the availability and use of MgSO4 for treatment
of severe pre-eclampsia and eclampsia. We developed
and tested a tool for rapidly assessing barriers and facili-
tators in the field. Zambia was chosen as the country for
this case study because its maternal mortality rate is
very high, 729/100 000 live births [11] and a recent
logistics system assessment for reproductive health com-
modities indicated that MgSO4 was not widely available
in health facilities in Zambia [12]. However, that assess-
ment did not explore the underlying reasons for its una-
vailability and previous studies investigating the
availability and use of MgSO4 injection have not
included Zambia.
Methods
Assessment Tool Development
We developed a rapid assessment instrument, that could
be used to investigate barriers and facilitators to the
availability and use of MgSO4 at different levels within a
health system in a resource poor setting. Identifying bar-
riers is the first step for designing and scaling up inter-
ventions to achieve use of medicines [10]. The ability to
identify and map barriers to specific areas of a health
system will enable decision makers to target interven-
tions in an efficient and cost-effective manner to
improve the availability and use of MgSO4 for the treat-
ment of severe pre-eclampsia and eclampsia. Before the
rapid assessment instrument could be developed a
model framework was requir e dt oi d e n t i f yw h a tw o u l d
need to be in place in a health system to ensure the
availability and use of MgSO4.
We used a fishbone (Ishikawa or cause and effect) dia-
gram [13] as the framework for identifying facilitators to
e n s u r et h ea v a i l a b i l i t ya n du s eo fM g S O 4 .Af i s h b o n e
diagram is an analysis tool that provides a systematic
way of looking at effects and the causes that create or
contribute to those effects. These diagrams have been
used in the software and manufacturing industries, for
product design, quality defect prevention, and to identify
potential factors causing an overall effect. In the health-
care field, the fishbone diagram has been used most
often as a continuous quality improvement tool to
examine the causes of a problem within a healthcare
setting. For example, Hartnell and colleagues [14] used
a fishbone diagram as a an analytic approach to identify
sources of medication errors in hospital. Ishikawa dia-
grams can be used to facilitate brainstorming exercises
to identify sources of a problem or to organize informa-
tion about known barriers or facilitators.
We chose the desired outcome of ‘rational use of
MgSO4 injection’ for the treatment of severe pre-
eclampsia and eclampsia, based on best available evi-
dence and guideline recommendations [3-6,15,16]
Rational use of medicines refers to the correct, proper
and appropriate use of medicines [17]. To define the
inputs for our fishbone diagram a literature search was
undertaken to identify country studies that had specifi-
cally looked at problems of availability and/or use of
magnesium sulphate for the treatment of severe pre-
eclampsia and eclampsia, in low and middle income
countries. The MEDLINE database was searched using
the OVIDsp search engine. The search used the search
term magnesium sul* combined with an individual
country name and magnesium sul* combined with the
term “developing countries”. No time, language or study
design limits were placed on the searches. The list of
countries was obtained from: http://www.listofcountrie-
softheworld.com/. Reference lists of relevant retrieved
studies were cross checked to identify further potentially
relevant studies and experts in the field were contacted.
The search focussed on studies investigating barriers to
the availability and use of MgSO4 and not on country
data regarding incidence rates of pre-eclampsia and
eclampsia. Three relevant studies were identified; two
were specifically about MgSO4 [8,9]; the third was a
study that described the investigation of barriers to a
range of reproductive health interventions, including use
of MgSO4 for eclampsia [18].
From the retrieved studies, we identified critical com-
ponents that would need to be in place in a public
health system in a resource poor setting to lead to
rational use of magnesium sulphate. These included:
inclusion of MgSO4 injection in the National Essential
Medicines List and Standard Treatment Guidelines;
registration in the country for use in the treatment of
severe pre-eclampsia and eclampsia; presence of a suita-
ble procurement procedure and distribution system; pre-
sence of a suitable local protocol developed by health
facilities providing basic or emergency obstetric care;
awareness of health professionals working in the facil-
ities that MgSO4 is the first line treatment for severe
pre-eclampsia and eclampsia; staff have been trained to
use MgSO4; and trained staff are available to administer
MgSO4 when necessary: In addition, pregnant women
need to be able to access to antenatal care, equipment
and supplies should be available to diagnose pre-
eclampsia and equipment and supplies should be avail-
able in the health facilities to administer MgSO4. The
completed fishbone diagram is shown in figure 1.
For each requirement listed in the fishbone diagram,
we identified the level in the health system where the
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available archival materials or observations. To facilitate
the rapid assessment, we focused on these data sources
rather than conducting interviews or surveys. The levels
identified were: government/regulatory; pharmaceutical
supply system; health facilities and health professionals.
Using this information we developed a rapid assessment
tool (checklist) for identifying potential barriers to the
availability and use of MgSO4 within the health system.
Additional information for the checklist for assessing the
pharmaceutical supply system came from Managing Drug
Supply: the selection, procurement, distribution, and use
of pharmaceuticals [19]. For the health facility section of
the checklist we developed a table, based on WHO guide-
lines [15,16], so that a walk-through exercise could be
undertaken to ascertain if the facility had sufficient quanti-
ties of MgSO4 to administer the recommended regimen
for the treatment of severe pre-eclampsia and eclampsia
and the necessary equipment to diagnose pre-eclampsia/
eclampsia and administer and monitor the use of MgSO4.
The full checklist can be found in additional file 1.
Data collection
We wished to assess the pharmaceutical sector and sup-
ply system in Zambia in order to identify barriers to the
availability of MgSO4 injection in health facilities for the
management of severe pre-eclampsia and eclampsia.
Barriers were assessed at the regulatory/government,
pharmaceutical supply system (supply, procurement, dis-
tribution), health facility and health professional levels.
An analysis of financing systems for the procurement of
essential medicines in Zambia was not possible at the
time of the study. The community level was not
included in the assessment because the rational use of
MgSO4 injection requires the patient to be in a health
facility. Assessing barriers at the community level
regarding access to health facilities was beyond the
scope of this study.
Based on the requirements, illustrated in the fishbone
diagram (figure 1), we aimed to collect data based on
analysis of public sector records and documents avail-
able in the public domain and routine observations at a
small pragmatic sample of health facilities providing
obstetric services in Lusaka District, Zambia. Lusaka dis-
trict was chosen for the pilot assessment because it has
the largest population of Zambia’s 72 districts and
includes the national capital, Lusaka. Lusaka district
contains the only Medical School in Zambia and the lar-
gest hospital in the country; the University Teaching
Hospital.
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Figure 1 Fishbone diagram identifying requirements for the rational use of Magnesium Sulphate in a health facility. File contains a
diagram illustrating what is required to facilitate the rational use of Magnesium Sulphate in a health facility
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At the government/regulatory level all the relevant policy
documents and guidelines were obtained from the Minis-
try of Health via the WHO Medicines Adviser for Zambia.
These documents included the most recent National Drug
Policy, National Reproductive Health Policy, National For-
mulary, National Essential Medicines List and National
Standard Treatment Guidelines. The Pharmaceutical Reg-
ulatory Authority was requested to provide information
about the licensing of MgSO4 in Zambia.
Pharmaceutical Supply System
Information about the procurement, supply and distri-
bution of MgSO4 within the public health system of
Zambia was obtained from Ministry of Health personnel
responsible for the procurement of medicines for the
public sector, employees at the Central Medical Store
and pharmacy workers in the visited health facilities.
Health Facilities
A walk through observational exercise was undertaken
at each health facility to ascertain if the facility had the
necessary supplies and equipment to: a) diagnose pre-
eclampsia/eclampsia, b) administer MgSO4 injection,
and c) monitor a patient receiving MgSO4 treatment of
severe pre-eclampsia or eclampsia. This was to assess
not only if MgSO4 was available on the day of the visit,
but also if the facility had sufficient quantity of MgSO4
to give the recommended treatment regimen to one
patient. Previous studies reporting the availability of
medicines for emergency obstetric care (EmOC) have
reported the presence or absence of medicines, but have
not reported if the quantities were sufficient to provide
the full course of treatment [12].
Health Professionals
A review of available undergraduate medical and mid-
wifery education and training materials was undertaken
to determine what pre-service training health profes-
sionals were receiving for the diagnosis and manage-
ment of pre-eclampsia and eclampsia.
Doctors and midwives were selected as these were the
health workers most likely to be managing patients with
pre-eclampsia and eclampsia and subsequently adminis-
tering magnesium sulphate injection.
Sample selection of health facilities
For this pilot assessment, a small pragmatic sample of
health facilities was visited, all within Lusaka District. As
there is no first level (district) or second level (provin-
cial) referral hospitals in Lusaka District, health centres
must refer complicated obstetric cases directly to the
University Teaching Hospital. Three health facilities
were visited: the University Teaching Hospital (UTH),
that has specialist obstetric services and is the largest
hospital in Zambia and two urban health centres, which
were reported to be providers of basic emergency obste-
tric care (EmOC). A facility is described as a provider of
basic EmOC when it can provide treatment for the
major complications of pregnancy, including administer-
ing an anticonvulsant for the treatment of pre-eclampsia
and eclampsia.
Data collection took place between 4
th and 14
th
August 2008.
Ethical approval
The research ethics committee of the WHO advised that
the study protocol satisfied the requirement for audit
and did not require formal approval. The Ministry of
Health, Zambia gave clearance for the assessment to
take place.
Results
Government/Regulatory Level
Magnesium sulphate injection was listed and recom-
mended in four key policy documents - the national
Essential Medicines List (2004), Zambian National For-
mulary (2005), the national Standard Treatment Guide-
lines (2004) and guidelines for pregnancy, childbirth,
postpartum and newborn care (2006). In the Zambian
National Formulary it is specified for use in cases of ful-
minant pre-eclampsia and eclampsia. The dosage regi-
mens recommended were consistent with research
evidence and international guidelines. The national
Standard Treatment Guidelines (2004) and the guide-
lines for pregnancy, childbirth, postpartum and newborn
care (2006) were not consistent in their recommenda-
tions for the use of MgSO4. The 2004 STGs gave
detailed instructions for the use of MgSO4 for the man-
agement of convulsions in eclampsia, but no informa-
tion for the use of MgSO4 for the prevention of
convulsions in severe pre-eclampsia. The 2006 guide-
lines did recommend the use of MgSO4 for the manage-
ment of both severe pre-eclampsia and eclampsia.
MgSO4 was not licensed in Zambia for the treatment
of severe pre-eclampsia or eclampsia at the time of the
assessment. In early 2008 an application was made to
the Pharmaceutical Regulatory Authority (PRA) by the
Ministry of Health (MoH) to have magnesium sulphate
registered for supply to the public sector. At the time of
the assessment, there was no record of any formal appli-
cations by private manufacturers or distributers to have
MgSO4 injection licensed and the Pharmaceutical Regu-
latory Authority were not aware of any local companies
which may be manufacturing MgSO4 injection. How-
ever, subsequent to this review the Pharmaceutical Reg-
ulatory Agency has licensed two private companies to
supply MgSO4.
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National procurement of medicines is carried out by the
Ministry of Health and is based on the national Essential
Medicines List. The central national medical store,
(Medical Stores Limited), manages the storage and dis-
tribution of medicines fort h eM o Ha n di st h em a i n
supplier of medicines to hospital pharmacies and district
health offices (DHO). Central and specialized hospitals,
such as the University Teaching Hospital, can get medi-
cines from the Central Medical Store, but they are also
given a grant by the MoH for the independent procure-
ment of emergency medicines and medical supplies.
Despite MgSO4 being on the EML, it had not been
procured by the MoH for several years and had been
out of stock at the Central Medical Store since 2006. As
a result, the district health office (DHO) for Lusaka Dis-
trict was also out of stock, as well as the two health cen-
tres within this district that were visited. The DHO was
not using its allowance for the procurement of MgSO4,
because it was reported that there was no demand from
the health centres. The pharmacy at the University
Teaching Hospital had MgSO4 in stock that was being
procured from a local wholesaler using the grant for
emergency medicines provided by the MoH. It was
being procured as a result of demand for MgSO4 injec-
tion from obstetricians working at the hospital. The
available stock of MgSO4 in the UTH pharmacy was
found to be manufactured in Zambia.
Copies of the Zambian National Formulary, National
Standard Treatment Guidelines (2004) and Essential
Medicines List were not available at any of the pharma-
cies or stores visited. A copy of the EML 2004 was avail-
able at the Government’s Central Medical Store,
Medical Stores Limited.
Health Facilities
The University Teaching Hospital was the only facility
to have MgSO4 injection in stock on the labour ward
on the day of the visit. MgSO4 was not available at the
two health centres. However, the health centres did
have the majority of the equipment and supplies neces-
sary for the diagnosis of pre-eclampsia/eclampsia and
administration of MgSO4 (see table 1). The notable
exception was calcium gluconate, which according to
international and national guidelines should always be
available when administering MgSO4 in case of toxicity.
At UTH, dipsticks for identifying proteinuria were out of
stock on the day of the visit. EDL and ZNF were not avail-
able in the health facilities. The national Standard Treat-
ment Guidelines (2004) and/or the Pregnancy, Childbirth,
Postpartum and Newborn Care Guidelines (2006) were
available in the health facilities visited. However, the local
protocols on display in the health centres did not follow
the recommended IV/IM regimen for MgSO4.
Health Professionals
The current undergraduate educational materials for
midwifery training (2004) included both theoretical and
practical training elements for the management of
severe pre-eclampsia and eclampsia with MgSO4. The
training and educational materials for the obstretric and
gynaecology rotation for medical students were not
available for review. The Director of the University
Teaching Hospital reported that medical students had to
complete a rotation in obstetrics and gynaecology both
before and after graduation and this included training in
the management of pre-eclampsia/eclampsia, using
MgSO4 as the first line treatment for these conditions.
All the midwives at the health facilities visited
reported that they had received pre-service training in
the diagnosis and management of pre-eclampsia and
eclampsia. None of the midwives on duty at the time of
the visit reported receiving any in-service training for
the administration and monitoring of MgSO4 for the
management of severe pre-eclampsia and eclampsia. It
was reported that some midwives from the health cen-
tres had attended an emergency obstetric care training
workshop. At the University Teaching Hospital, MgSO4
is the recommended first line treatment and the hospital
has its own treatment protocol, which is consistent with
research evidence and international guidelines. Checking
for proteinuria was reported to be a problem due to fre-
quent stock outs of dipsticks. Dipsticks were out of
stock on the day of the visit. The University Teaching
Hospital is the only referral hospital in Lusaka district
for all complicated antenatal and obstetric cases. It was
reported that many of the referrals from health centres
are for pregnancy induced hypertension (PIH). However,
on arrival at UTH the patients actually have eclampsia
and require treatment with MgSO4. During the visits to
the health facilities, no doctors were available to verify
their pre- and post-service training in the management
of pre-eclampsia/eclampsia.
See table 2 for a summary of the major barriers and
facilitators identified at each level during the rapid
assessment exercise
Discussion
O u rs t u d yi st h ef i r s ts t u d yw ea r ea w a r eo ft ot r yt o
identify barriers to the availability and use of MgSO4
using a health system approach. We found that the cur-
rent situation in Zambia shows that research knowledge
regarding magnesium sulphate for the treatment of
severe eclampsia and eclampsia has been translated into
policy. However, implementation of policy into practice
was found to be limited at the lower levels of care.
Numerous barriers to the availability and use of MgSO4
were identified within the health system, including a
lack of stock. There was a lack of dissemination of
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Equipment and Supplies which are required for the use of MgSO4 Health Facility
UTH Health Centre
1
Health Centre
2
Local treatment protocols exist for eclampsia and recommend magnesium sulphate as the first line
treatment
Yes Yes Yes
Local treatment protocols exist for pre-eclampsia and recommend magnesium sulphate as the first line
treatment
Yes Yes Yes
Sphygmomanometer or BP machine Yes Yes Yes
Stethoscope Yes Yes Yes
Dipsticks to detect protein in the urine No Yes Yes
Sufficient quantity of MgSO4 to provide 24 h treatment for 1 patient Yes No No
Calcium gluconate (1 g, 10 ml of 10% solution) Yes No No
2% Lignocaine (1 ml ampoules) Yes Yes Yes
Cannulae Yes Yes Yes
Sterile syringes (10 ml or 20 ml) Yes Yes Yes
Sterile needles Yes Yes Yes
Sterile water or normal saline for dilution of MgSO4 Yes Yes Yes
Normal saline or Ringer’s lactate Yes Yes Yes
Drip stand Yes Yes Yes
IV giving sets Yes Yes Yes
Patella hammer Yes No No
Urinary catheters Yes Yes Yes
Urine collection bags No Yes Yes
Sharps boxes for safe waste disposal Yes Yes Yes
Gloves Yes Yes Yes
Table 2 Major barriers and facilitators to the availability and use of MgSO4 identified at each level
Barriers identified Facilitators identified Outcome
Government/
Regulatory
MgSO4 injection not registered
in Zambia
MgSO4 not licensed for use in
severe pre-eclampsia or
eclampsia
MgSO4 listed in Essential Medicines List and
Standard Treatment Guidelines
MgSO4 being manufactured in Zambia
Unregulated MgSO4 available in the
market place
Pharmaceutical supply
system
MgSO4 not being procured by
MoH
MgSO4 out of stock at the
Central Medical Store
MgSO4 on Ministry of Health Procurement
list
MgSO4 not available for delivery to
health facilities
University Teaching
Hospital (UTH)
Stock-outs of dipsticks for
testing urine for proteinuria.
STG translated into suitable local protocol
Health professionals aware that MgSO4 is
the 1
st line treatment for severe pre-
eclampsia/eclampsia
Obstetricians requested purchase of MgSO4
Hospital pharmacy is procuring MgSO4 from
local wholesaler
Midwives have received training for use of
MgSO4
Evidence that MgSO4 being used for
treatment of eclampsia, but not severe
pre-eclampsia
Health Centre 1
Health Centre 2
(findings at the two
health centres were
the same)
MgSO4 out of stock
Midwife on duty had never
administered MgSO4
Local protocol did not follow
evidence-based guidelines for
use of MgSO4
Midwife on duty aware that MgSO4 is the
first line treatment for severe pre-eclampsia
and eclampsia
Evidence-based guidelines available
Equipment and supplies available to
diagnose pre-eclampsia
Equipment and supplies available to
administer MgSO4
No evidence of use of MgSO4. Cases of
eclampsia treated with diazepam and
referred to UTH
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and pharmacies and a general lack of in-service training
for both midwives and pharmacists regarding the correct
use of MgSO4. The demand for MgSO4 at the health
centre level was reported to be low. However, as this
assessment did not include an audit of clinical data it is
not clear if this was because there were in fact few cases
or that cases were being misdiagnosed. There can be no
demand if there is failure to diagnose the condition. It
should be noted that the health centres visited during
the study period did have the necessary equipment and
medical supplies to diagnose pre-eclampsia and eclamp-
sia. At the health centre level, due to the low demand
from the midwives, MgSO4 was not considered to be a
priority medicine by the pharmacists in charge of pro-
curement. As a result they were not putting pressure on
the Central Medical Store to make it available.
While pre-eclampsia and eclampsia are clearly impor-
tant causes of maternal mortality globally, the absolute
frequency of cases presenting to an individual facility
may be low. Although we did not assess clinical records,
the anecdotes from staff suggested that cases of pre-
eclampsia were infrequent at small hospitals. If this is
correct, then lack of recent knowledge and experience
would be another potential barrier to effective adminis-
tration of MgSO4 and would highlight the need for fre-
quent refresher courses and other educational
reminders, to ensure appropriate diagnosis and
treatment.
Poor availability of magnesium sulphate may also
reflect limitations of procurement systems. Magnesium
sulphate was not supplied to the lower levels of care
because it was out of stock at the Central Medical Store.
The demand for MgSO4 at the health centre level was
apparently low, but it is not clear if the problem of
availability was due to lack of demand leading to a lack
of supply or vice versa.
During the development of the rapid assessment tool
it was suggested that the lack of licensing of MgSO4
injection was a key potential barrier to the availability
and use of MgSO4 and this may have contributed to it
not being available at the district facilities. The Univer-
sity Hospital Pharmacy, following demand from obstetri-
cians, was able to procure locally manufactured
magnesium sulphate, but the lack of registration clearly
raises uncertainty about the quality of the product. As
an injectable medicine, the manufacture of magnesium
s u p h a t en e e d st ob ec l o s e l ym o n i t o r e dt oe n s u r et h a t
the ampoules are not contaminated during the manufac-
turing process.
In the walk through exercise at health facilities, apart
from the quantity of MgSO4 required for the treatment
of one patient for 24 hours, only the presence or
absence of the other essential supplies and equipment
required for the diagnosis, administration and monitor-
ing of MgSO4 was evaluated, and not the quality or
quantity of them. Clearly, the total stock and quality of
supplies and equipment could have a bearing on the
actual delivery of care and rational use of MgSO4 for
the treatment of severe pre-eclampsia and eclampsia.
The main limitation of this case study is that it
involved a small number of facilities in one district in
Zambia, in the capital city and thus the findings may
not reflect the current situation in other districts/pro-
vinces of Zambia. However, it is likely that MgSO4
availability in the capital city and surrounding district
represents the most optimistic picture of the supply and
use situation within Zambia. Follow-up studies should
include public and private sector health facilities and
pharmacies in other districts, including rural areas.
Other limitations of our study include the lack of finan-
cial data regarding the cost of MgSO4 and its affordabil-
ity, and the lack of information regarding the availability
of MgSO4 injection in the private sector.
Ideally, qualitative methods could have been used to
assess the knowledge and experience of staff at health
facilities in relation to use of magnesium sulphate. How-
ever, our intention was to develop a rapid assessment
instrument that might be applied in a variety of settings.
Therefore our data sources needed to be publicly avail-
able archival materials and observations. Future assess-
ments could be expanded to incorporate a qualitative
method to uncover potential barriers to the use of
MgSO4 injection by doctors and midwives in clinical
practice. The role of community members, community
health workers and traditional birth attendants in recog-
nizing risk factors for pre-eclampsia and development of
eclampsia was beyond the scope of this study. However,
it should be noted that educational interventions to
increase awareness of the risk factors for the develop-
ment of severe pre-eclampsia/eclampsia at this level
may have an impact on the number of referrals to
health facilities and consequently on demand for
MgSO4.
Since undertaking our study we have become aware of
other frameworks that have been used to analyse access
to health technologies in resource poor settings [20].
There is still much to learn in this complex area and
awareness of different approaches will enable the ulti-
mate assessment instrument to be developed. Although
our instrument does have limitations, it gathers useful
information on barriers in an efficient way without dis-
ruption of health care provision.
The successful translation of research evidence into
clinical practice is a complex process. Many studies
[9,21,22] have concentrated on mechanisms for translat-
ing research evidence into policy. What is suggested by
this assessment is that although the policy makers - as
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lines - have been persuaded by the evidence, the gap in
this case is the translation from policy into action plans.
To close this gap requires an integrated approach
throughout the pharmaceutical sector and pathways for
clinical care that simultaneously responds to all of the
factors identified in the fishbone diagram. Such a strat-
egy would include acting on the recommendations listed
in Table 3. The challenge is developing methods to
implement such a strategy successfully in fragile health
systems and resource limited settings. In order to deter-
mine if our recommendations are sufficient and appro-
priate for turning policy into practice further
operational research is required. Our recommendations
need to be implemented and evaluated using a rigorous
methodology.
Conclusions
The study highlights the complicated issue of ensuring
that essential medicines are available and used appropri-
ately. The fishbone diagram is a good way to illustrate
the complexity of translating research findings into clini-
cal practice. Access to a medicine is a complex con-
struct because medicines not only have to be available
within the health system, they have to be prescribed and
in some cases, such as MgSO4, also administered by a
health professional, before patients can benefit from
their effects and health outcomes can be improved.
Much work remains to be done at the level of individual
countries to understand these factors better. There is a
need to move beyond simply determining whether a
medicine is available in the Central Medical Store or
health-care facility towards considering prescribing prac-
tices, the relevance and appropriateness of standard
treatment guidelines and factors that facilitate appropri-
ate use by health professionals.
This study shows that it is feasible to undertake a sys-
tem based approach for assessing availability of key
essential medicines. Ideally, it should be complemented
by independent interviews or focus groups to determine
the knowledge and understanding of the use of the
medicines concerned. However, even without that infor-
mation, it is possible to identify a number of barriers to
the use of magnesium sulphate that can be addressed,
such as the licensing of an appropriate product, supply
and dissemination of relevant treatment guidelines, and
educational reminders. Any intervention to promote use
of magnesium sulphate as a tool for reducing maternal
mortality will need to take these factors into account.
Additional material
Additional file 1: Checklist for identifying barriers to the availability
and use of Magnesium Sulphate Injection. File contains the rapid
assessment tool used to collect information for the study.
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